Literature DB >> 12728468

Simple retrograde balloon dilation for treatment of ureteral strictures: etiology-based analysis.

Seok-Soo Byun1, Jeong Hyun Kim, Seung-June Oh, Hyeon Hoe Kim.   

Abstract

This study consists of an analysis of the results of simple retrograde balloon dilation in the treatment of ureteral strictures for the evaluation of the long-term efficacy of this procedure, and the factors affecting its success rate. A prospective study was performed on 43 ureteral strictures (22 malignant, 21 benign) from 37 patients treated with retrograde balloon dilation from October 1997 to May 1999. After the stricture segments were dilated, ureteral stents were indwelled uniformly for 3 weeks. Strictures were postoperatively followed up radiographically at 1, 3, 6 and 12 months, and annually thereafter. Success was defined by symptomatic and radiographic improvement. The follow-up periods ranged from 8 to 57 months (mean 41 months). The success rates of the benign strictures at 12 and 36 months were much higher than those of the malignant strictures (67 and 57% vs., 18 and 14%, p=0.0009). While 56% and 47% of the patients with strictures shorter than 2 cm were successful at 12 and 36 months, respectively, none with strictures longer than 2 cm were successful at the same follow-up periods (p=0.0002). Of the successful benign cases with a shorter segment at 12 months, 12 out of 14 (86%) showed persistent long-term successes at the 36 months follow-up. Other prognostic factors, such as sex, age, location, disappearance of a waist, dilation time and grade of hydronephrosis, were not found to influence the success rate. A multivariate analysis revealed the etiology and stricture length were the only significant prognostic factors affecting the final outcome (p=0.030 and p=0.0262, respectively, by Cox's proportional hazards model). In consideration of its minimal invasiveness and acceptable long-term outcome, simple retrograde balloon dilation is an effective treatment modality for benign ureteral stricture with a short segment (< or = 2 cm), and a shorter duration of stenting (3-weeks) is viable.

Entities:  

Mesh:

Year:  2003        PMID: 12728468     DOI: 10.3349/ymj.2003.44.2.273

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  7 in total

Review 1.  Current status of minimally invasive endoscopic management of ureteric strictures.

Authors:  Stefanos Kachrilas; Andreas Bourdoumis; Theocharis Karaolides; Stavroula Nikitopoulou; George Papadopoulos; Noor Buchholz; Junaid Masood
Journal:  Ther Adv Urol       Date:  2013-12

2.  Endoscopic Management of Ureteral Stricture: NYU Case of the Month, August 2018.

Authors:  Philip Zhao
Journal:  Rev Urol       Date:  2018

Review 3.  Endoscopic Management of Ureteral Strictures: an Update.

Authors:  Jacob W Lucas; Eric Ghiraldi; Jeffrey Ellis; Justin I Friedlander
Journal:  Curr Urol Rep       Date:  2018-03-02       Impact factor: 3.092

4.  Preliminary Outcomes of Different Tactics of Ureteral Stent Placement in Patients with Ureteral Stricture Undergoing Balloon Dilatation: Experience from a Large-Scale Center.

Authors:  Xiao Hu; Dechao Feng; Xin Wei
Journal:  Front Surg       Date:  2022-05-16

Review 5.  Minimal-invasive management of urological complications after kidney transplantation.

Authors:  Susanne Deininger; Silvio Nadalin; Bastian Amend; Martina Guthoff; Nils Heyne; Alfred Königsrainer; Jens Strohäker; Arnulf Stenzl; Steffen Rausch
Journal:  Int Urol Nephrol       Date:  2021-03-02       Impact factor: 2.370

6.  A nomogram to predict stricture-free survival in patients with ureteral stricture after balloon dilation.

Authors:  Jintao Hu; Cong Lai; Mingchao Gao; Kaiwen Li; Wang He; Dingjun Zhu; Wenlian Xie; Haihua Wu; Meijuan Xu; Jian Huang; Jinli Han
Journal:  BMC Urol       Date:  2021-09-16       Impact factor: 2.264

7.  Ureteral Stricture after Laparoscopic Tubal Ligation due to Suturing of the Serosa.

Authors:  Berat Cem Ozgür; Ahmet Metin Hasçiçek; Tolga Karakan; Cem Nedim Yücetürk; Erim Ersoy
Journal:  Case Rep Urol       Date:  2012-10-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.